STALICLA-SA
11.4.2024 13:01:32 CEST | Business Wire | Press release
STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411118139/en/
Thomas Blaettler, MD, joins STALICLA as Chief Medical Officer. (Photo: Business Wire)
Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights to help progress STALICLA’s ambitions in CNS conditions. He is a board-certified neurologist with 30 years’ experience in neuroscience, both in clinical residency and within the industry (Novartis, BMS, Roche, Orphazyme, Coave Therapeutics, Vectura Fertin Pharma).
As a clinician, he is driven by the desire to advance clinical research for the benefit of patients who are in dire need of better treatments. He has published both preclinical and clinical research articles in top-tier journals such as Nature, Cell, PNAS and Lancet. With time, he has assumed roles with increasing strategic responsibility, overseeing global clinical development programs from Phase 1 to Phase 3.
Thomas has profound regulatory experience across the globe (EMA, FDA, PMDA, CFDA) from pre-IND interaction to submissions of NDAs and MAAs. As Chief Medical Officer at Orphazyme, he established a clinical development and regulatory organization, overseeing four late-stage development programs. In recent years, he was instrumentally involved in two successful IPOs at the Copenhagen and New York Nasdaq stock exchanges. Thomas completed his Doctor of Medicine at the University of Zurich and gained board certification from the Swiss Society of Neurology in 2003.
“We are delighted to welcome Thomas during a pivotal time where his proven track record in navigating clinical and strategic development will support the advancement of STALICLA’s late-stage Phase 2 and 3 clinical pipelines for precision medicine treatment of neurological and neuropsychiatric disorders. His focus on biomarker lead strategies in CNS drug development is an ideal fit with our science and vision to pioneer precision medicine in the neurodevelopmental disorder space.” - Lynn Durham, CEO & Founder.
“I am thrilled to be joining STALICLA, a biotechnical company that is leading the way in future precision medicine in NDDs and other CNS disorders. Moving away from the one size fits all concept in drug development, with modest if at all treatment effects, to tailored treatments that take into account the clinical and pathophysiological heterogeneity of patient populations will revolutionize the way we treat patients.”- Thomas Blaettler, MD.
About STALICLA
STALICLA SA is a Swiss clinical-stage biopharmaceutical company, pioneering precision treatment in neurodevelopmental and neuropsychiatric disorders. With an advanced clinical pipeline of phase 2 and 3 ready assets and an AI-driven precision neuro medicine platform for patient-drug matching, STALICLA is changing the landscape of brain disease treatment. For more information, please visit: https://stalicla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411118139/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release
Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release
Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
